Brukinsa, illustration of capsule form (not a photo of the actual pack)

Illustrative image.

Brukinsa

Zanubrutinib

Prescription required

$31560.00

80mg · 3 × 120 capsules · 6 months supply

BrandBranded medicine· By BeiGene

$5260.00 per month

How long a supply?

6 months$5260.00 a month
Supplied from Israel

Test mode: no payment is taken. View cart

Annual cost

$63120a year at this pack size

Prescription required

Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.

About Brukinsa

Overview

Brukinsa (zanubrutinib) is a prescription medicine supplied as capsules for treating certain blood cancers in adults. It is used for Waldenström’s macroglobulinemia, chronic lymphocytic leukemia and small lymphocytic lymphoma. It is also used for mantle cell lymphoma after at least one prior treatment; marginal zone lymphoma that has returned or not responded after at least one anti-CD20 treatment; and, with obinutuzumab, follicular lymphoma that has returned or not responded after two or more systemic treatments. It works by blocking Bruton’s tyrosine kinase (BTK), a protein involved in signals that help B cells multiply and move within the body.

What it treats

Brukinsa is used in adults to treat: - Mantle cell lymphoma (MCL) after at least one previous treatment. - Waldenström’s macroglobulinemia (WM). - Marginal zone lymphoma (MZL) that has returned or not responded to treatment, after at least one anti-CD20-based treatment regimen. - Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). - Follicular lymphoma (FL) that has returned or not responded to treatment, together with obinutuzumab, after at least two previous lines of systemic treatment.

Safety information

Side effects

Common side effects of Brukinsa include low neutrophil counts (a type of white blood cell), low platelet counts, upper respiratory tract infections, bleeding, and muscle or bone pain. Serious risks include bleeding, infections (including opportunistic infections), low blood cell counts, new cancers (including skin cancers), abnormal heart rhythms, and liver injury. Contact your doctor if you notice bleeding, signs of infection, or symptoms of an abnormal heart rhythm. Blood counts and liver function need monitoring during treatment. Use sun protection because of the risk of skin cancer. Brukinsa can harm an unborn baby; women who could become pregnant should use effective contraception.

When to call your doctor

- Seek medical attention immediately for bleeding. - Seek medical attention immediately for signs or symptoms of infection. - Seek medical attention immediately for an irregular heartbeat.

If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.

Before taking this medicine

The FDA label lists no contraindications for Brukinsa. Caution and monitoring are needed for bleeding, infections (including opportunistic infections), low blood cell counts, abnormal heart rhythms and liver injury. Blood counts and liver function should be monitored during treatment. Other cancers, including skin cancers, have occurred; monitoring and sun protection are advised. Brukinsa can harm an unborn baby. Women who could become pregnant should use effective contraception. Do not breastfeed during treatment.

Interactions

Tell your doctor if you take medicines that are moderate or strong CYP3A inhibitors, as your Brukinsa dose may need adjustment. Strong or moderate CYP3A inducers should generally not be taken with Brukinsa. If a moderate CYP3A inducer is used, your prescriber may recommend adjusting your Brukinsa dose.

Using Brukinsa

Dosing

Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.

Storage

Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.

Clinical information on this page is summarised from the US FDA label BRUKINSA (ZANUBRUTINIB) CAPSULE BRUKINSA (ZANUBRUTINIB) TABLET, FILM COATED [BEONE MEDICINES USA, INC.] (DailyMed, retrieved 19 September 2026).

Reviews

No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.

  • Every prescription order is checked by a licensed pharmacist before dispensing.
  • Payment pages are encrypted and card details never reach our servers.
  • We ship internationally, with cold-chain packing where a medicine needs it.

Related medicines